Abstract：
OBJECTIVE: This study aimed to report pain during and following injection for trigger finger as well as failure to resolve triggering. We hypothesized that a corticosteroid injection alone would be equally or less painful compared with the standard combination of corticosteroid and lidocaine for the treatment of trigger fingers, and there would be no difference in the resolution of triggering.
METHODS: Our study was a prospective, single-blinded, randomized controlled trial at a single institution, comprising 76 patients with a diagnosis of trigger finger. Each treatment group consisted of 38 patients. Patients were randomized to receive either a betamethasone (1 mL, 6 mg) injection without lidocaine or a betamethasone injection (1 mL, 6 mg) with 1% lidocaine (1 mL). Patients were assessed during injection and at 1 hour, 6 hours, 2 days, and 6 weeks after the injection. The primary outcome was pain measured using a numerical rating scale. The secondary outcome was the rate of failure to resolve symptoms at 6 weeks.
RESULTS: There was a statistically significant difference in pain scores between the lidocaine and betamethasone versus betamethasone-only injections during administration (4.6 vs 6.2) and after 1 hour (1.3 vs 2.5). There was no statistically significant difference in pain scores after 6 hours (1.5 vs 2.0) and 2 days (0.7 vs 0.6) or in failure rate at the 6-week time point (21% vs 18%).
CONCLUSIONS: This study showed that there is a statistically significant difference in pain during and shortly after injection when using a steroid with lidocaine versus steroid alone for the treatment of trigger finger, but that difference may not be clinically relevant. There was no significant difference in the failure rate between the treatments.
METHODS: Therapeutic II.
METHODS: Our study was a prospective, single-blinded, randomized controlled trial at a single institution, comprising 76 patients with a diagnosis of trigger finger. Each treatment group consisted of 38 patients. Patients were randomized to receive either a betamethasone (1 mL, 6 mg) injection without lidocaine or a betamethasone injection (1 mL, 6 mg) with 1% lidocaine (1 mL). Patients were assessed during injection and at 1 hour, 6 hours, 2 days, and 6 weeks after the injection. The primary outcome was pain measured using a numerical rating scale. The secondary outcome was the rate of failure to resolve symptoms at 6 weeks.
RESULTS: There was a statistically significant difference in pain scores between the lidocaine and betamethasone versus betamethasone-only injections during administration (4.6 vs 6.2) and after 1 hour (1.3 vs 2.5). There was no statistically significant difference in pain scores after 6 hours (1.5 vs 2.0) and 2 days (0.7 vs 0.6) or in failure rate at the 6-week time point (21% vs 18%).
CONCLUSIONS: This study showed that there is a statistically significant difference in pain during and shortly after injection when using a steroid with lidocaine versus steroid alone for the treatment of trigger finger, but that difference may not be clinically relevant. There was no significant difference in the failure rate between the treatments.
METHODS: Therapeutic II.
摘要：
目的：本研究旨在报告扳机指注射过程中和注射后的疼痛以及无法解决的触发。我们假设，与皮质类固醇和利多卡因的标准组合治疗扳机指相比，单独注射皮质类固醇同样或更痛苦。触发的分辨率没有区别。
方法：我们的研究是前瞻性的，单盲,在单一机构进行的随机对照试验，包括76名诊断为触发手指的患者。每个治疗组由38名患者组成。患者随机接受倍他米松(1mL，6mg）不含利多卡因或倍他米松注射液（1mL，6mg)加1%利多卡因(1mL)。在注射期间和1小时时对患者进行评估，6小时,2天,注射后6周。主要结果是使用数字评定量表测量的疼痛。次要结果是在6周时未能解决症状的比率。
结果：在给药期间（4.6vs6.2）和1小时后（1.3vs2.5），利多卡因和倍他米松与仅注射倍他米松之间的疼痛评分有统计学上的显着差异。在6小时（1.5vs2.0）和2天后（0.7vs0.6）的疼痛评分或在6周时间点的失败率（21％vs18％）没有统计学上的显着差异。
结论：这项研究表明，使用利多卡因类固醇与单独使用类固醇治疗扳机指时，注射过程中和注射后不久的疼痛有统计学上的显着差异，但这种差异可能与临床无关.治疗之间的失败率没有显着差异。
方法：治疗II。
方法：我们的研究是前瞻性的，单盲,在单一机构进行的随机对照试验，包括76名诊断为触发手指的患者。每个治疗组由38名患者组成。患者随机接受倍他米松(1mL，6mg）不含利多卡因或倍他米松注射液（1mL，6mg)加1%利多卡因(1mL)。在注射期间和1小时时对患者进行评估，6小时,2天,注射后6周。主要结果是使用数字评定量表测量的疼痛。次要结果是在6周时未能解决症状的比率。
结果：在给药期间（4.6vs6.2）和1小时后（1.3vs2.5），利多卡因和倍他米松与仅注射倍他米松之间的疼痛评分有统计学上的显着差异。在6小时（1.5vs2.0）和2天后（0.7vs0.6）的疼痛评分或在6周时间点的失败率（21％vs18％）没有统计学上的显着差异。
结论：这项研究表明，使用利多卡因类固醇与单独使用类固醇治疗扳机指时，注射过程中和注射后不久的疼痛有统计学上的显着差异，但这种差异可能与临床无关.治疗之间的失败率没有显着差异。
方法：治疗II。
